Skip to search formSkip to main contentSkip to account menu

PF 04948568

Known as: Anti-EGFRvIII Vaccine CDX-110, PF04948568, L-Cysteine, L-leucyl-L-alpha-glutamyl-L-alpha-glutamyl-L-lysyl-L-lysylglycyl-L-asparaginyl-L-tyrosyl-L-valyl-L-valyl-L-threonyl-L-alpha-aspartyl-L-histidyl-S-(1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)-, complex with hemocyanin (Megathura crenulata) 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

rindopepimut

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Interim data for ACT III: Phase II trial of PF-04948568 (CDX-110) in combination with temozolomide (TMZ) in patients (pts) with glioblastoma (GBM).
2014 Background: EGFRvIII is a constitutively activated mutation of EGFR, not expressed in normal tissues but expressed in GBM… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)